ZS Pharma is a biopharmaceutical company committed to the development and commercialization of highly selective, non-absorbed drugs to treat renal, cardiovascular, liver and metabolic diseases. Our initial focus is on the development of ZS-9, our product candidate in Phase 3 development for the treatment of hyperkalemia, a life-threatening condition characterized by abnormally high levels of potassium in the blood.
We are advancing ZS-9 through clinical development with the goal of obtaining approval for the treatment of acute and chronic hyperkalemia, regardless of the underlying disease state. Learn more about the results from our pivotal Phase 3 clinical trial in patients with hyperkalemia here.
Keep up to date with the latest ZS Pharma News and Updates
ZS Pharma Secures $20 Million in Debt FinancingDownload PDF
ZS Pharma Completes Patient Enrollment in ZS004, Its Second Phase 3 Study of ZS-9 in Patients with HyperkalemiaDownload PDF
ZS Pharma Announces Allowance of Two U.S. Patent Applications for ZS-9Download PDF